SCHEMBL7220705

SCHEMBL7220705

COC(=O)C1CC[C@@](C)(C(=O)O)C1(C)C

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.60
CYP2C9 P11712 1/20 0.60
TSHR P16473 1/20 0.60
CYP2C19 P33261 1/20 0.60
ALDH1A1 P00352 3/20 0.58
LMNA P02545 2/20 0.55
POLB P06746 1/20 0.55
NPSR1 Q6W5P4 4/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
ATM Q13315 2/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HTT P42858 1/20 0.46
TP53 P04637 1/20 0.46
HIF1A Q16665 1/20 0.34
PPM1B O75688 1/20 0.33
PTPN1 P18031 1/20 0.33
PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2533909 1.00 CYP1A2 (0.60) CYP1A2CYP2C9TSHRCYP2C19ALDH1A1
SCHEMBL2534532 1.00 CYP1A2 (0.60) CYP1A2CYP2C9TSHRCYP2C19ALDH1A1
SCHEMBL7227981 1.00 CYP1A2 (0.60) CYP1A2CYP2C9TSHRCYP2C19ALDH1A1
SCHEMBL986291 1.00 CYP1A2 (0.60) CYP1A2CYP2C9TSHRCYP2C19ALDH1A1
SCHEMBL2535775 0.88 CYP1A2 (0.50) CYP1A2CYP2C9TSHRCYP2C19ALDH1A1
SCHEMBL2534983 0.88 CYP1A2 (0.50) CYP1A2CYP2C9TSHRCYP2C19ALDH1A1
SCHEMBL2534980 0.88 CYP1A2 (0.50) CYP1A2CYP2C9TSHRCYP2C19ALDH1A1
SCHEMBL1335665 0.85 ALDH1A1 (0.54) CYP1A2CYP2C9TSHRCYP2C19ALDH1A1
SCHEMBL16386442 0.85 CYP1A2 (0.56) CYP1A2CYP2C9TSHRCYP2C19ALDH1A1
SCHEMBL12699010 0.85 CYP1A2 (0.56) CYP1A2CYP2C9TSHRCYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6596752-B1 Small molecules that are potent inhibitors of alpha 4 beta 1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. TANABE SEIYAKU CO., LTD. (JP) 2003-07-22 US disclosed
US-20030130349-A1 Inhibitors of alpha 4beta1 mediated cell adhesion TANABE SEIYAKU CO., LTD. 2003-07-10 US disclosed
US-6482849-B1 Inhibitors of α4β1 mediated cell adhesion TANABE SEIYAKU CO., LTD. (JP) 2002-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130349-A1 Inhibitors of alpha 4beta1 mediated cell adhesion VCAM1, ICAM1, ITGB1 CYP1A2 1888/4885CYP2C9 3367/4885TSHR 4066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.